
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is positively viewed because strong bookings, including B2B above 1.2x for four consecutive quarters and 1.3x TTM direct-fee B2B, suggest revenue visibility well into 2027 even if growth moderates from recent peaks. Execution has improved across large pharma, biotech, FSO, FSP, labs, and evidence generation, while AI-enabled workflow gains are reducing cycle times and supporting margin expansion, with gross margin up 90 bps sequentially and EBITDA margin up to 16.6%. The business also has balance-sheet strength and capital returns, generating $302 million of free cash flow in 3Q and repurchasing $400 million of stock, while industry tailwinds like improving biotech funding, rising INDs, and near-COVID clinical trial starts support durable demand.
Bears say
Icon is exposed to a CRO market that can weaken if government regulation, macroeconomic softness, or biopharma consolidation reduces sponsors’ willingness and ability to fund outsourced research. The downside case already assumes only low-single-digit top-line growth and EBITDA margin degradation in 2027, with valuation anchored at 11.0x the downside EBITDA estimate and peer minimum 3-year multiples. Further accounting reviews, backlog reductions, delayed trials from slower patient enrollment or site selection, and talent-driven wage inflation could pressure confidence, bookings, margins, and the company’s reputation.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ICON (ICLR) Forecast
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares